About this Research Topic
Lung cancer remains to be one of the leading causes of global morbidity and mortality. There are two subtypes of lung cancer known as non-small cell lung carcinoma (NSCLC), which is the most common type accounting for approximately 85% of cases and small cell lung carcinoma, accounting for 15% of cases. NSCLC is then divided into three further histological subtypes known as lung adenocarcinoma (LUAD) which is the main histological subtype accounting for 40% of all cases, squamous cell carcinoma, and large cell carcinoma. Although there have been significant developments in treatment and therapies of lung cancer, the 5-year survival rate for lung cancer patients is less than 20%. Therefore, further studies are required to understand alternative methods of treatment to improve the prognosis and overall survival rate.
Non-coding RNAs (ncRNAs) do not have the potential to code protein but are known as involved in cell functioning and have been found to play a role in cancer. ncRNAs include long non-coding RNAs (lncRNAs), which have been found to regulate gene expression at epigenetic, transcriptional, and post-transcriptional stages. and microRNAs (miRNAs), which are commonly known as oncogenes or tumor-suppressor genes dependent on their function that either promote or inhibit the progression of tumors. The lncRNA, GCC2-AS1 has been studied to understand it's role in malignant tumors which remain to be poorly understood. Studies have involved evaluating the changes in expression level of GCC2-AS1 and analysing the effects in lung adenocarcinoma. Studies involving the effects and impact of lncRNA deepen our understanding of how they can potentially be a diagnostic and prognostic biomarker for lung cancer.
This Research Topic welcomes Original Research, Reviews, Systematic Reviews, Mini Reviews and Perspectives with a focus on the role of long non-coding RNAs in the progression and influence of lung cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Non-coding RNAs (ncRNAs) do not have the potential to code protein but are known as involved in cell functioning and have been found to play a role in cancer. ncRNAs include long non-coding RNAs (lncRNAs), which have been found to regulate gene expression at epigenetic, transcriptional, and post-transcriptional stages. and microRNAs (miRNAs), which are commonly known as oncogenes or tumor-suppressor genes dependent on their function that either promote or inhibit the progression of tumors. The lncRNA, GCC2-AS1 has been studied to understand it's role in malignant tumors which remain to be poorly understood. Studies have involved evaluating the changes in expression level of GCC2-AS1 and analysing the effects in lung adenocarcinoma. Studies involving the effects and impact of lncRNA deepen our understanding of how they can potentially be a diagnostic and prognostic biomarker for lung cancer.
This Research Topic welcomes Original Research, Reviews, Systematic Reviews, Mini Reviews and Perspectives with a focus on the role of long non-coding RNAs in the progression and influence of lung cancer.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: lung cancer, long non-coding RNA, therapy, NSCLC, gene expression, RNA
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
